Revolution Medicines announced unprecedented Phase 3 results in pancreatic cancer
Arctic Aurora LifeScience holding, Revolution Medicines announced outstanding overall survival benefit in metastatic pancreatic cancer, one of the most lethal tumors.
On 13 April, the oncology company Revolution Medicines disclosed the results of their RASolute 302 Phase 3 trial, which tested daraxonrasib as a treatment for metastatic pancreatic cancer. This oral, once-daily molecule was compared to the standard chemotherapy treatment for this patient group, which is administered intravenously. Patients receiving daraxonrasib showed a median overall survival of 13.2 months, almost double that of the control group at 6.7 months. This difference is highly clinically meaningful.
Revolution Medicines plans to submit these results to the FDA for approval. The company expects an accelerated timeline, as the molecule has been selected for the FDA Commissioner's National Priority Voucher programme, which aims to streamline the regulatory process for selected drugs.
This could provide a new treatment option for pancreatic cancer patients, who urgently need more effective and targeted therapies. Around 500,000 people are diagnosed with this tumour worldwide every year. Due to the lack of early symptoms, most tumours are only detected once metastasis or a secondary tumour has occurred. This contributes to the malignancy's aggressiveness, with only 3% of patients currently surviving for more than 5 years.
Daraxonrasib targets the disease by suppressing signalling through a protein called RAS, which is often mutated in cancer patients and acts as a main driver of uncontrolled tumour growth.
These landmark results were clearly rewarded by the investment community, with Revolution’s stock appreciating by more than 41% after the announcement.
Latest news
Arctic Asset Management - Markedskommentar mars 2026
Markedene i mars ble påvirket av krigen i Iran som har spredt seg til store deler av Midtøsten og skapt betydelige globale ringvirkninger. Etter at USA og Israel angrep Iran på den siste dagen i februar, har regionen vært preget av krigshandlinger, med påfølgende avbrudd i råvareproduksjon og forsyningskjeder som har gitt økt markedsvolatilitet.
Arctic Asset Management - No slowing down of Biotech M&A: Soleno to be acquired by Neurocrine
On April 6, Arctic Aurora LifeScience holdings Soleno Therapeutics and Neurocrine Biosciences announced an agreement in which the mid-cap commercial biotech Neurocrine acquires Soleno for USD 2.9 billion or USD 53 per share - a 34% premium over the last closing price.
Arctic Asset Management - Apellis to be acquired by Biogen for 140% premium
On March 31, Arctic Aurora LifeScience portfolio company Apellis Pharmaceuticals announced that the company had agreed to be acquired by Biogen for an upfront cash consideration of USD 5.6 billion, representing a 140% premium on the latest closing price.
Arctic Asset Management - Arctic Midt i Måneden - Global uro, energisjokk og markedsmuligheter
Geopolitisk uro, stigende energipriser og økt markedsvolatilitet preger finansmarkedene i mars. Hva betyr dette for renter, aksjer og investorers posisjonering fremover? I denne episoden av Arctic Midt i Måneden diskuterer Albert Collett sammen med Cathrine Foyn, Tone Varmann og Alexander Larstedt Lager hvordan krig og usikkerhet påvirker markedene – og hvor mulighetene kan ligge i en urolig tid.
Arctic Asset Management - Unlocking Alpha in Biotech Through Active Selection
Yesterday, two companies in the Arctic Aurora LifeScience portfolio reported positive clinical data, which was rewarded by the market. Clinical execution and identifying companies with differentiated drug candidates yields excess returns, as demonstrated by Xenon's share price, which appreciated by close to 50% on positive data, and Dianthus, which appreciated by 21%.
Arctic Asset Management - An AI sector winner
Artificial intelligence (AI) is often portrayed as a disruptive force. In the pharmaceutical and biotechnology industries, however, it should primarily be understood as a structural value driver, enhancing productivity, improving capital efficiency and strengthening long-term competitive positioning. By compressing timelines in the discovery process and improving efficiency at the clinical and commercial stages, AI-based tools can reduce costs and meaningfully improve industry economics.